These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 19718394)

  • 41. Efficacy of strontium ranelate on bone mineral density in men with osteoporosis.
    Ringe JD; Dorst A; Farahmand P
    Arzneimittelforschung; 2010; 60(5):267-72. PubMed ID: 20533764
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study.
    Ringe JD; Faber H; Dorst A
    J Clin Endocrinol Metab; 2001 Nov; 86(11):5252-5. PubMed ID: 11701687
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of a combined alendronate and calcitriol agent (Maxmarvil) on bone metabolism in Korean postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study.
    Rhee Y; Kang M; Min Y; Byun D; Chung Y; Ahn C; Baek K; Mok J; Kim D; Kim D; Kim H; Kim Y; Myoung S; Kim D; Lim SK
    Osteoporos Int; 2006 Dec; 17(12):1801-7. PubMed ID: 17019520
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of Alendronate for the Prevention of Bone Loss in Calcar Region Following Total Hip Arthroplasty.
    Yukizawa Y; Inaba Y; Kobayashi N; Choe H; Kubota S; Saito T
    J Arthroplasty; 2017 Jul; 32(7):2176-2180. PubMed ID: 28318867
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of renal transplant recipients with low bone mineral density: a randomized prospective trial of alendronate, alfacalcidol, and alendronate combined with alfacalcidol.
    Trabulus S; Altiparmak MR; Apaydin S; Serdengecti K; Sariyar M
    Transplant Proc; 2008; 40(1):160-6. PubMed ID: 18261575
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Alfacalcidol in men with osteoporosis: a prospective, observational, 2-year trial on 214 patients.
    Ringe JD; Farahmand P; Schacht E
    Rheumatol Int; 2013 Mar; 33(3):637-43. PubMed ID: 22527138
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hip fracture protection by alendronate treatment in postmenopausal women with osteoporosis: a review of the literature.
    Iwamoto J; Sato Y; Takeda T; Matsumoto H
    Clin Interv Aging; 2008; 3(3):483-9. PubMed ID: 18982918
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Potency of a combined alfacalcidol-alendronate therapy to reduce the risk of falls and fractures in elderly patients with glucocorticoid-induced osteoporosis.
    Ringe JD; Schacht E; Dukas L; Mazor Z
    Arzneimittelforschung; 2011; 61(2):104-11. PubMed ID: 21428245
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : results of FACTS -international.
    Reid DM; Hosking D; Kendler D; Brandi ML; Wark JD; Weryha G; Marques-Neto JF; Gaines KA; Verbruggen N; Melton ME
    Clin Drug Investig; 2006; 26(2):63-74. PubMed ID: 17163237
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of bone mineral density in reducing fracture risk in patients receiving alendronate plus alfacalcidol therapy.
    Itoi E; Uemura Y; Ohta H; Nakamura T; Fukunaga M; Orimo H; Shiraki M
    J Orthop Sci; 2021 Nov; 26(6):1085-1093. PubMed ID: 33358235
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Postmenopausal osteoporosis. Digital Rx radiogrammetry in the diagnosis and follow-up of treatment with alfacalcidol].
    Galeşanu C; Ciubotariu C; Melnic G; Galeşanu MR
    Rev Med Chir Soc Med Nat Iasi; 2006; 110(4):833-41. PubMed ID: 17438884
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Alendronate protects premenopausal women from bone loss and fracture associated with high-dose glucocorticoid therapy.
    Okada Y; Nawata M; Nakayamada S; Saito K; Tanaka Y
    J Rheumatol; 2008 Nov; 35(11):2249-54. PubMed ID: 19031508
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.
    Lems WF; Lodder MC; Lips P; Bijlsma JW; Geusens P; Schrameijer N; van de Ven CM; Dijkmans BA
    Osteoporos Int; 2006; 17(5):716-23. PubMed ID: 16463007
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Systematic review of raloxifene in postmenopausal Japanese women with osteoporosis or low bone mass (osteopenia).
    Fujiwara S; Hamaya E; Sato M; Graham-Clarke P; Flynn JA; Burge R
    Clin Interv Aging; 2014; 9():1879-93. PubMed ID: 25395843
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status.
    Langdahl BL; Marin F; Shane E; Dobnig H; Zanchetta JR; Maricic M; Krohn K; See K; Warner MR
    Osteoporos Int; 2009 Dec; 20(12):2095-104. PubMed ID: 19350340
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Three-year experience with alendronate treatment in postmenopausal osteoporotic Japanese women with or without renal dysfunction: a retrospective study.
    Iwamoto J; Sato Y; Uzawa M; Takeda T; Matsumoto H
    Drugs Aging; 2012 Feb; 29(2):133-42. PubMed ID: 22233456
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis.
    Kim SW; Park DJ; Park KS; Kim SY; Cho BY; Lee HK; Shin CS
    Endocr J; 2005 Dec; 52(6):667-74. PubMed ID: 16410657
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial.
    Khan AA; Bilezikian JP; Kung AW; Ahmed MM; Dubois SJ; Ho AY; Schussheim D; Rubin MR; Shaikh AM; Silverberg SJ; Standish TI; Syed Z; Syed ZA
    J Clin Endocrinol Metab; 2004 Jul; 89(7):3319-25. PubMed ID: 15240609
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study.
    Hosking D; Adami S; Felsenberg D; Andia JC; Välimäki M; Benhamou L; Reginster JY; Yacik C; Rybak-Feglin A; Petruschke RA; Zaru L; Santora AC
    Curr Med Res Opin; 2003; 19(5):383-94. PubMed ID: 13678475
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Teriparatide vs. alendronate as a treatment for osteoporosis: changes in biochemical markers of bone turnover, BMD and quality of life.
    Panico A; Lupoli GA; Marciello F; Lupoli R; Cacciapuoti M; Martinelli A; Granieri L; Iacono D; Lupoli G
    Med Sci Monit; 2011 Aug; 17(8):CR442-448. PubMed ID: 21804463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.